Jazz Pharmaceuticals’ strategic positioning in the industry was highlighted recently at the ASCO25 conference, where they presented new cancer data. With a rich history that includes contributions to the development of Keytruda, Jazz Pharmaceuticals has carved out a unique niche for itself in the oncology arena. Despite a smaller workforce compared to industry heavyweights such […]
Tag: AstraZeneca
Ionis Pharmaceuticals: RNA Medicines Leader
“””Ionis Pharmaceuticals, Inc. is a leading biotech firm specializing in RNA-targeted medicines within the United States. With a dedication to innovation and a focus on developing groundbreaking treatments, Ionis is making a profound impact on the biotech landscape. Their expansive portfolio includes pioneering treatments like TRYNGOLZA for familial chylomicronemia syndrome, WAINUA for hereditary transthyretin-mediated amyloidosis, […]
EU Approval for AstraZeneca Calquence Regimens in CLL
The European Union (EU) has granted approval to AstraZeneca’s Calquence-based regimens for the treatment of previously untreated chronic lymphocytic leukaemia (CLL) in adults. The endorsement comes on the heels of impressive results from the AMPLIFY Phase III trial, which underscored the efficacy of these novel treatments in CLL management. Calquence, medically known as acalabrutinib, is […]
Europe Approves AstraZeneca’s Calquence Combo for CLL
Europe has given its approval to AstraZeneca’s fixed-duration Calquence combination for the treatment of chronic lymphocytic leukemia (CLL), a type of cancer that is often slow-growing but can become harder to treat over time. This decision, backed by a positive opinion from the European Medicines Agency’s (EMA) scientific panel, is fueled by compelling data from […]
EC Approval for AstraZeneca’s Calquence in CLL Treatment
Chronic lymphocytic leukaemia (CLL) is the most prevalent form of leukaemia in adults, with an estimated 27,000 cases diagnosed in key European countries in 2024. Despite being deemed incurable, patients often endure prolonged treatment, such as AstraZeneca’s Calquence, which has now received approval from the European Commission for first-line use against CLL. This development marks […]
Daiichi Sankyo’s Future with ADC Cancer Drugs
Daiichi Sankyo’s ADC cancer drug, Enhertu, generated $3.7 billion in sales and is meeting expectations. However, challenges lie ahead for Datroway and the lead program with Merck. Despite U.S. approval for Datroway, Daiichi Sankyo faces hurdles in lung cancer development due to mixed study results and a recent setback with Merck on another ADC application. […]
AstraZeneca Pharma Reports 48% Profit Increase in Q4 FY25
AstraZeneca Pharma, a Bengaluru-based pharmaceutical company, saw a significant 48% increase in net profit to Rs 58.25 crore in the fourth quarter of fiscal year 2025. The company’s results were announced after market hours, leading to a 0.78% rise in share prices to Rs 7,980 apiece on the NSE. This positive financial performance reflects the […]
